Oncternal Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 30
- Market Cap
- -
- Website
- http://www.oncternal.com
- Introduction
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Oncternal Therapeutics, Inc
- Target Recruit Count
- 59
- Registration Number
- NCT05917470
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸XCancer Omaha, Omaha, Nebraska, United States
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
- Conditions
- Relapsed/Refractory Aggressive B-Cell Malignancies
- Interventions
- Drug: Bridging Therapy
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Oncternal Therapeutics, Inc
- Target Recruit Count
- 57
- Registration Number
- NCT05588440
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Lymphatic DiseasesImmunoproliferative DisordersLymphoma, Mantle-CellImmune System DiseasesLymphoma, Non-HodgkinLymphomaLymphoproliferative DisordersLymphoma, B-Cell
- Interventions
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Oncternal Therapeutics, Inc
- Registration Number
- NCT05431179
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
- Conditions
- B-cell Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMarginal Zone LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Oncternal Therapeutics, Inc
- Target Recruit Count
- 95
- Registration Number
- NCT03088878
- Locations
- 🇺🇸
City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
🇺🇸Sanford Stem Cell Clinical Center at UCSD, La Jolla, California, United States
🇺🇸UC Davis Comprehensive Cancer Center, Sacramento, California, United States
TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Oncternal Therapeutics, Inc
- Target Recruit Count
- 85
- Registration Number
- NCT02657005
- Locations
- 🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Children's Hospital of Colorado, Aurora, Colorado, United States
🇺🇸Children's National Hospital, Washington, District of Columbia, United States
News
Oncternal Therapeutics Sells ROR1-Targeting Programs to Ho'ola Therapeutics for $68 Million Deal
Oncternal Therapeutics has sold its zilovertamab monoclonal antibody and ONCT-808 CAR-T cell therapy programs to Ho'ola Therapeutics for $3 million upfront and up to $65 million in milestone payments.
Sonoma Biotherapeutics Strengthens Leadership Team with Appointment of Rajesh Krishnan as Chief Technical Officer
• Sonoma Biotherapeutics has appointed Rajesh Krishnan, Ph.D., as Chief Technical Officer to advance their engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases. • Dr. Krishnan brings over 25 years of industry experience in process development and manufacturing, most recently serving as CTO and CSO at Oncternal Therapeutics with previous leadership roles at Dynavax, Gilead, Merck, Amgen, and Pfizer. • The strategic appointment comes at a crucial time for the clinical-stage biotech company as they continue developing novel treatments aimed at restoring immune system balance through proprietary Treg cell therapy platforms.
Robust Pipeline for Ewing Sarcoma Treatment: 25+ Companies Advancing Novel Therapies
A comprehensive pipeline analysis reveals over 25 pharmaceutical companies actively developing treatments for Ewing Sarcoma, with multiple promising candidates in various clinical stages.
ONCT-534 Shows Promise in Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics' ONCT-534 demonstrates potential in treating relapsed or refractory metastatic castration-resistant prostate cancer (mCRPC).
Pembrolizumab Approved for Mesothelioma; Patritumab Deruxtecan Shows Promise in NSCLC
FDA has expanded the approval of pembrolizumab (Keytruda) in combination with pemetrexed and cisplatin for previously untreated advanced/metastatic malignant pleural mesothelioma.
Oncternal Therapeutics Halts B-Cell Lymphoma Trial and Explores Strategic Alternatives
Oncternal Therapeutics discontinues its Phase 1/2 trial of ONCT-808, a CAR-T therapy targeting ROR1, for relapsed/refractory aggressive B-cell lymphoma due to strategic considerations.
Oncternal Therapeutics Halts Clinical Trials, Initiates Layoffs After Disappointing Results
Oncternal Therapeutics discontinues clinical trials for ONCT-534 in prostate cancer and ONCT-808 in B-cell lymphoma due to lackluster Phase I results and a patient death.